Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Novartis Bids On "Superstatin": Seeking U.S. Rights To Pitavastatin

  • News

Executive Summary

Novartis is in negotiations for the U.S. rights to pitavastatin with Sankyo and Nissan Chemicals, CEO Daniel Vasella, MD, told the New York Society of Securities Analysts June 5.

You may also be interested in...



Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation

Novartis is conducting additional trials to determine whether the antipsychotic iloperidone has a dose-dependant QTc prolongation side effect before it files an NDA for the agent.

Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation

Novartis is conducting additional trials to determine whether the antipsychotic iloperidone has a dose-dependant QTc prolongation side effect before it files an NDA for the agent.

AstraZeneca Crestor Copromotion Decision Coming: Nexium Has 6% Share

AstraZeneca expects to make a decision on whether to use a copromotion partner for the HMG-CoA reductase inhibitor Crestor (rosuvastatin) within "the next six to eight weeks," CFO Jonathan Symonds told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.

Table

View full table

Tags:
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS037998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By